Moderna
Whoa! How did you get here? This company profile is not meant to be publicly available. Research on this company is incomplete, and the overall rating has been disabled, but while you are here feel free to have a look at the info we do have.
OVERALL |
|
Owned |
USA |
Rating |
N/A |
Biotechnology
The company's only commercial product is the Moderna COVID-19 vaccine.
Moderna Inc | USA | website |
Company Assessment
PRAISE | CRITICISM | INFORMATION | ||
Moderna Inc | ||||
JUST Capital polls Americans every year to identify the issues that matter most in defining just business behaviour. For their 2024 rankings the public identified 20 issues, which are organised under the headings Workers, Communities, Customers, Shareholders and Environment. JUST Capital then define metrics that map to those issues and track and analyse the largest, publicly traded U.S. companies. This analysis powers their rankings, in which this company ranked 248th of 937 companies, and 15th of 41 Pharmaceuticals & Biotech companies.
Source: JUST Capital (2024) |
In February 2016, a Nature editorial criticised Moderna for not publishing any peer-reviewed papers on its technology, unlike most other emerging and established biotech companies, and compared its approach to that of the controversially failed Theranos.
Source: Nature (2016)
In 2022 the median pay for a worker at this company was US$163,293. The CEO was paid 119 times this amount. Exorbitant CEO pay is a major contributor to rising inequality. CEOs are getting more because of their power to set pay, not because they are increasing productivity or possess specific, high-demand skills. The economy would suffer no harm if CEOs were paid less (or taxed more). In contrast, the CEO-to-typical-worker compensation ratio was 20-to-1 in 1965 and 58-to-1 in 1989.
Source: AFL-CIO (2023)
This company is a member of the AMR Industry Alliance, a coalition of biotech, diagnostics, generics and research-based pharmaceutical companies set up to provide sustainable solutions to curb antimicrobial resistance (AMR). AMR is an increasingly significant threat to global public health which puts at risk the effective prevention and treatment of a wide range of infections.
Source: AMR Industry Alliance (2021)
This company has responsibility claims on its website under the headings Medicines for Patients, Employees, Environment, Community, Governance & Ethics, CSR Policies & Data.
Source: company website (2021)
This company received an S&P Global ESG Score of 50/100 in the Biotechnology category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 23 Sep 2022). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.
Source: S&P Global (2022) |
Company Details
Type | Public company |
Founded | 2010 |
Revenue | 803 million USD (2020) |
Employees | 1,500 (2021) |
Contact Details
Address | USA |
Website | www.modernatx.com |